Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07608718 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 2 study, sponsored by Pedro Barata, MD, MSc.
- Not yet
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT07608718 is a Phase 2 study that has not yet begun recruiting, run by Pedro Barata, MD, MSc. The registered enrollment target is 19 participants.
The verdict
NCT07608718, a Phase 2 study, has not yet begun recruiting, sponsored by Pedro Barata, MD, MSc.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as they experience clinical benefit from it. The purpose of this study is to learn if Zanzalinitib is effective in treating metastatic castrate-resistant prostate cancer.
Interventions
- DRUG Zanzalintinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2026-09 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07608718
The ClinicalTrials.gov registry entry for NCT07608718 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pedro Barata, MD, MSc, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT07608718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07608718 about?
NCT07608718 is a clinical study titled "Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer". This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as ...
What is the current status of trial NCT07608718?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2026-09. Estimated completion is 2030-05.
What interventions are being tested in trial NCT07608718?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT07608718?
This trial is sponsored by Pedro Barata, MD, MSc, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.